Aman M. G. et al. (2005)
Acute and long-term safety and tolerability of risperidone in children with autism.
Journal of Child and Adolescent Psychopharmacology
15(6), pp. 869-884
Aman M. G. et al. (2008)
Cognitive effects of risperidone in children with autism and irritable behavior.
Journal of Child and Adolescent Psychopharmacology
18(3), pp. 227-236
Aman M. G. et al. (2015)
Journal of Child and Adolescent Psychopharmacology
August, 25(6), pp. 482-493.
Anderson G. M. et al. (2007)
Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.
February, 61(4), pp. 545-550.
Brentani H. et al. (2013)
Autism spectrum disorders: an overview on diagnosis and treatment.
Revista Brasileira de Psiquiatria
35 S 62-72.
Carroll D. et al. (2014)
Child and Adolescent Psychiatric Clinics of North America
January, 23(1), pp. 57-72.
Erickson C. A. et al. (2014)
STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study.
Journal of Autism and Developmental Disorders
44(4), pp. 958-964.
Kaplan G. , McCracken J. T. (2012)
Psychopharmacology of autism spectrum disorders.
Pediatric Clinics of North America
59(1), pp. 175-187
Lindsay R. L. et al. (2006)
Journal of Intellectual and Developmental Disability
December, 31(4), pp. 204-209.
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
American Journal of Psychiatry
161(6), pp. 1125-1127
McCracken J. T. et al. (2002)
Risperidone in children with autism and serious behavioral problems.
New England Journal of Medicine
347(5), pp. 314-321
Safety issues with drug therapies for autism spectrum disorders.
Journal of Clinical Psychiatry
66 pp. 32-37
McDougle C. J. et al. (2000)
Child and Adolescent Psychiatric Clinics of North America
January, 9(1), pp. 201-224.